Crapaxone has continued to grow and it's growth was not just due to price. According to the latest IMS weekly prescription data, Crapaxone's market share is just short of 32% of NRx’s. It continues to take market share and it was one of only two MS products that continued to grow share year-over-year.
>…you can bet that Crapaxone will be cannibalized further and can achieve growth only through price increases<
Ridiculing a drug that is doing $1.5B a year in global sales and is number one in its category may win you some points on the ELN board on iVillage, but not here.
Market Data 
Markets 
AI
